Jubilant Ingrevia has reported robust financial results for the fourth quarter and full fiscal year ended March 31, 2026. Revenue saw a 12% year-over-year increase in Q4, driven by strong volume growth and strategic price improvements. EBITDA also grew significantly, reflecting improved operational efficiency and a favorable product mix. The company highlighted successful navigation of market challenges and progress across its ‘Pinnacle Journey’ strategic pillars.
Jubilant Ingrevia Reports Strong Q4 FY26 Financials
Jubilant Ingrevia Limited announced its financial results for the fourth quarter (Q4) and full fiscal year (FY26) ending March 31, 2026, showcasing a period of significant growth and operational resilience. The company reported a 12% year-over-year increase in revenue for Q4 FY26, reaching ₹1,179 crore. Total EBITDA for the quarter rose by 11% year-over-year to ₹172 crore, with EBITDA margins improving to 15% from 13% in the previous year. Profit After Tax (PAT) after exceptional items saw a substantial 17% year-over-year increase to ₹86 crore.
Full Year FY26 Performance Highlights
For the full fiscal year 2026, total revenue grew by 5% to ₹4,388 crore. Total EBITDA for FY26 increased by 9% to ₹607 crore, with EBITDA margins standing at 14%. PAT after exceptional items for the year was ₹278 crore, an increase of 11% year-over-year. Basic and Diluted EPS for FY26 stood at ₹18, an 11% increase compared to the previous year.
Strategic Growth Drivers and Business Segment Updates
The company’s performance was bolstered by strong execution and strategic initiatives. Key highlights for the quarter included successful handling of the Middle East crisis with no production loss, the dispatch from its newly constructed Agro CDMO facility, and the acquisition of Remidex to enhance its Human Nutrition business. The Board has recommended a final dividend of ₹2.50 per share.
Specialty Chemicals
The Specialty Chemicals segment revenue grew by 6% year-over-year to ₹516 crore in Q4 FY26. EBITDA for the segment increased by 8% year-over-year to ₹139 crore, with EBITDA margins at a strong 27%. For FY26, segment revenue was ₹1,937 crore (up 7% YoY), and EBITDA was ₹510 crore (up 21% YoY).
Nutrition & Health Solutions
Revenue from the Nutrition & Health Solutions segment increased by 21% year-over-year to ₹230 crore in Q4 FY26. EBITDA saw a 9% year-over-year growth to ₹32 crore. For FY26, segment revenue was ₹790 crore (up 6% YoY), with EBITDA at ₹100 crore.
Chemical Intermediates
The Chemical Intermediates segment revenue grew by 15% year-over-year to ₹433 crore in Q4 FY26. However, EBITDA for the segment decreased by 32% year-over-year to ₹22 crore due to challenging market conditions and input cost pressures. For FY26, segment revenue was ₹1,662 crore (up 3% YoY), with EBITDA at ₹73 crore.
‘Pinnacle Journey’ Progress
Jubilant Ingrevia emphasized the progress made under its ‘Pinnacle Journey’ strategy, focusing on building a strong foundation for future growth. The company highlighted achievements in customer engagement, operations, R&D, and strategic partnerships. The acquisition of Remidex Pharma was noted as a key step to strengthen its Human Nutrition Premixes portfolio. The construction of the Gajraula Multi Purpose Plant (MPP) is progressing well, expected to further enhance its CDMO growth roadmap.
Future Outlook
Looking ahead to FY27, Jubilant Ingrevia anticipates growth to be led by Specialty Chemicals and Nutrition, with a recovery expected in Acetyls. The company is projecting sequential growth in revenue and EBITDA starting from Q1 FY27.
Source: BSE
